Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI combined with apatinib for unresectable metastatic colorectal cancer
ChiCTR1800015308Phase 4Recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Mar 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib, irinotecan, fluorouracil and folinic acid in colorectal cancer (CRC), sponsored by Shanxi Cancer Hospital. Primary endpoint: Progression-free survival. Started Mar 2017; status: recruiting.
02
Drugs
Rivoceranibirinotecanfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR1800015308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015308.